Form 8-K - Current report:
SEC Accession No. 0001104659-23-031393
Filing Date
2023-03-13
Accepted
2023-03-13 06:02:02
Documents
12
Period of Report
2023-03-13
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm239325d1_8k.htm   iXBRL 8-K 31388
  Complete submission text file 0001104659-23-031393.txt   206403

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA apre-20230313.xsd EX-101.SCH 3024
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE apre-20230313_lab.xml EX-101.LAB 34476
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE apre-20230313_pre.xml EX-101.PRE 22589
6 EXTRACTED XBRL INSTANCE DOCUMENT tm239325d1_8k_htm.xml XML 3606
Mailing Address 3805 OLD EASTON ROAD DOYLESTOWN PA 18902
Business Address 3805 OLD EASTON ROAD DOYLESTOWN PA 18902 267-370-5219
Aprea Therapeutics, Inc. (Filer) CIK: 0001781983 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39069 | Film No.: 23725540
SIC: 2834 Pharmaceutical Preparations